Scarica l'app Stockscreener
105.88
1.97%
-2.13
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché NUVL Giù?
Forum
Previsione
Precedente Chiudi:
$108.01
Aprire:
$106.95
Volume 24 ore:
1.22M
Relative Volume:
2.24
Capitalizzazione di mercato:
$7.12B
Reddito:
-
Utile/perdita netta:
$-224.29M
Rapporto P/E:
-27.15
EPS:
-3.9
Flusso di cassa netto:
$-185.06M
1 W Prestazione:
+9.72%
1M Prestazione:
+8.95%
6M Prestazione:
+43.74%
1 anno Prestazione:
+14.18%
Intervallo 1D:
$105.64
$109.78
Intervallo di 1 settimana:
$93.30
$112.88
Portata 52W:
$55.53
$112.88
Nuvalent Inc Stock (NUVL) Company Profile
Nome
Nuvalent Inc
Settore
Industria
Telefono
508-446-2272
Indirizzo
ONE BROADWAY, 14TH FLOOR, CAMBRIDGE
Confronta NUVL con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
NUVL
Nuvalent Inc
|
105.88 | 7.85B | 0 | -224.29M | -185.06M | -3.90 |
|
VRTX
Vertex Pharmaceuticals Inc
|
426.76 | 107.15B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
755.90 | 77.46B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
436.38 | 58.90B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
918.92 | 56.55B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
198.76 | 42.58B | 447.02M | -1.18B | -906.14M | -6.1812 |
Nuvalent Inc Stock (NUVL) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-11-12 | Iniziato | Canaccord Genuity | Buy |
| 2025-10-16 | Ripresa | Stifel | Buy |
| 2025-10-15 | Iniziato | Cantor Fitzgerald | Overweight |
| 2025-09-04 | Ripresa | Guggenheim | Buy |
| 2025-09-03 | Iniziato | Raymond James | Outperform |
| 2025-08-19 | Iniziato | Piper Sandler | Overweight |
| 2025-03-14 | Aggiornamento | UBS | Neutral → Buy |
| 2024-12-30 | Iniziato | H.C. Wainwright | Buy |
| 2024-10-24 | Iniziato | UBS | Neutral |
| 2024-08-29 | Iniziato | Barclays | Overweight |
| 2024-04-17 | Iniziato | Jefferies | Buy |
| 2024-04-01 | Aggiornamento | Leerink Partners | Market Perform → Outperform |
| 2024-02-28 | Ripresa | Guggenheim | Buy |
| 2024-02-23 | Iniziato | Robert W. Baird | Outperform |
| 2023-09-27 | Iniziato | Stifel | Buy |
| 2023-08-08 | Iniziato | SVB Securities | Market Perform |
| 2023-07-24 | Iniziato | Guggenheim | Buy |
| 2023-01-18 | Iniziato | Wedbush | Outperform |
| 2022-06-24 | Iniziato | BMO Capital Markets | Outperform |
Mostra tutto
Nuvalent Inc Borsa (NUVL) Ultime notizie
FDA accepts NDA for Nuvalent's zidesamtinib for non-small cell lung cancer - MSN
Four companies raise nearly $950M in follow-ons: Public Equity Report - BioCentury
Nuvalent Announces $500M Stock Offering Pricing - The Globe and Mail
Biotech Stock Gets Booted in Latest Fund Update - AOL.com
Will Nuvalent Inc. stock keep outperforming rivalsJuly 2025 Chart Watch & Advanced Swing Trade Entry Alerts - newser.com
Why analysts upgrade Nuvalent Inc. stockJuly 2025 Weekly Recap & Technical Pattern Based Buy Signals - newser.com
Sidley Represents Nuvalent in Pricing of US$500 Million Public Offering - Legal Desire Media and Insights
Jefferies raises Nuvalent stock price target to $164 on promising cancer drug data - Investing.com Nigeria
[8-K] Nuvalent, Inc. Reports Material Event | NUVL SEC FilingForm 8-K - Stock Titan
Nuvalent Announces FDA Acceptance of New Drug Application for Zidesamtinib for the Treatment of TKI Pre-treated Patients with Advanced ROS1-positive NSCLC - The Malaysian Reserve
Can Nuvalent Inc. stock surprise with earnings upsideWeekly Trade Report & Safe Capital Growth Plans - newser.com
Will Nuvalent Inc. stock reach Wall Street targetsPortfolio Return Report & Accurate Buy Signal Notifications - newser.com
FDA accepts Nuvalent’s zidesamtinib application for lung cancer treatment By Investing.com - Investing.com Nigeria
Nuvalent Insider Sold Shares Worth $2,065,030, According to a Recent SEC Filing - MarketScreener
Nuvalent Gets FDA Review of Zidesamtinib for ROS1-Positive Lung Cancer - MarketScreener
Nuvalent Executives Sell Over $4.6 Million in Stock - TradingView
CFO Balcom Sells 20,729 ($2.1M) Of Nuvalent Inc [NUVL] - TradingView
[Form 4] Nuvalent, Inc. Insider Trading Activity - Stock Titan
[424B5] Nuvalent, Inc. Prospectus Supplement (Debt Securities) - Stock Titan
Nuvalent announces FDA acceptance of new drug application for zidesamtinib for the treatment of TKI pre-treated patients with advanced ROS1-positive NSCLC - MarketScreener
Can Nuvalent Inc. stock rebound after recent weaknessJuly 2025 Pullbacks & Weekly High Conviction Trade Ideas - newser.com
Analysts Offer Insights on Healthcare Companies: Johnson & Johnson (JNJ) and Nuvalent (NUVL) - The Globe and Mail
Using economic indicators to assess Nuvalent Inc. potentialStock Surge & Free Technical Confirmation Trade Alerts - newser.com
What momentum indicators show for Nuvalent Inc. stockJuly 2025 Gainers & Safe Capital Growth Stock Tips - newser.com
Nuvalent Prices $500 Million Common Stock Offering - MarketScreener
Nuvalent prices $500 million public offering at $101 per share By Investing.com - Investing.com Nigeria
Nuvalent Announces Pricing of Public Offering of Common Stock - Finviz
Nuvalent prices $500 million public offering at $101 per share - Investing.com India
Nuvalent prices 4.95 million shares in public offering at $101.00 per share - MarketScreener
Nuvalent Prices 4.95 Million Shares In Public Offering At $101.00 Per Share - TradingView
Nuvalent Inc Azioni (NUVL) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
1.38%
1.42%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):